- Company is marketing five-part deal, expected to price Monday
- Deal will also help pay dividends, potential early redemptions
Roche Holding AG is selling investment-grade debt in the US corporate bond market on Monday to help fund its acquisition of Telavant Holdings Inc.
The Swiss pharmaceutical giant is marketing the deal in five parts, with pricing on the longest-dated portion — a 10-year note — being discussed at 115 basis points to 120 basis points over the benchmark rate, according to a person familiar with the matter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.